Details: pack, label wording, sources, registration
Bestoxol 40 mg/ml (4%), Eye drops
eye drops, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Potential topical adjunctive use of exact Bestoxol taurine 4% eye drops for canine cataract, corneal injury/dystrophy, retinal disease or glaucoma
Not rateable
No numerical score assigned
Details →
vetman assessment
Bestoxol
×
40 mg/ml (4%), eye drops, human medicine
Assessed clinical scope Dog · Potential topical adjunctive use of exact Bestoxol taurine 4% eye drops for canine cataract, corneal injury/dystrophy, retinal disease or glaucoma · Into the eye
Care setting Veterinarian-directed use only after a complete diagnosis and only if a defensible patient-specific rationale exists without delaying established medical or surgical care
vetman score
Not rateable
No numerical score assigned
Evidence confidence: Medium
Georgia: Yes, human · № რ-033806 · Verified on 22 Oct 2026
Off-label use
Not rateable
A numerical product score cannot responsibly be assigned. Exact Bestoxol has a verifiable human formulation and Georgian registration, but no exact-product canine dose, ocular PK, target-animal safety or clinical outcome study was found. The only located canine topical study used a multi-ingredient antioxidant containing taurine plus N-acetyl carnosine, glutathione, cysteine ascorbate and riboflavin in an unmasked preliminary design, so neither its effect nor regimen can be attributed or transferred to Bestoxol.
Taurine biology is real, but it does not create a product-specific veterinary claim. Bestoxol should remain an identity-documented, no-dose, not-rateable human ophthalmic product until direct dog/cat efficacy and safety evidence supports a defined clinical scope.
Important safety and use flags
No exact-product dog/cat efficacy, ocular PK, target-animal safety or dose study was found. Do not convert the human label or mechanistic taurine literature into a veterinary product score. Feline taurine deficiency is a nutritional/systemic disorder. Diagnose diet and systemic status and correct dietary taurine; topical Bestoxol is not proven to deliver therapeutic retinal taurine or reverse established degeneration. The preliminary canine cataract study tested a multi-ingredient antioxidant formulation, not Bestoxol or taurine alone. Its unmasked, nonplacebo design and combined actives cannot establish this product’s efficacy or regimen. Do not copy the human two-drop, multi-month cataract/corneal-trauma or glaucoma schedule. No diagnosis-independent dog/cat frequency or course is published here. Do not delay established diagnosis or treatment of cataract, corneal injury, retinal disease, glaucoma, uveitis or infection. Progressive pain, redness, opacity, discharge, pressure change or vision loss requires prompt ophthalmic reassessment. The exact solution contains methyl parahydroxybenzoate. Stop and reassess for irritation, lid swelling, erythema, pruritus or another hypersensitivity reaction; target-animal repeated-dose tolerance is unknown. Avoid dropper-tip contact with the eye, lashes, skin or fingers, recap promptly and do not share a bottle between patients. Follow the exact pack’s storage and post-opening instructions. Safety in pregnant, lactating, breeding or juvenile dogs and cats is not established. Use only after an explicit veterinary benefit-risk decision, and do not infer safety from taurine being a normal nutrient. Current Georgian human registration does not imply veterinary authorisation or efficacy. The controlled EU/GB/US exact-brand negative findings describe market status only and are not used as proof that the product is ineffective. Assessment sources +
Close
Cat
Potential topical adjunctive use of exact Bestoxol taurine 4% eye drops for feline cataract, corneal injury/dystrophy, retinal disease or glaucoma
Not rateable
No numerical score assigned
Details →
vetman assessment
Bestoxol
×
40 mg/ml (4%), eye drops, human medicine
Assessed clinical scope Cat · Potential topical adjunctive use of exact Bestoxol taurine 4% eye drops for feline cataract, corneal injury/dystrophy, retinal disease or glaucoma · Into the eye
Care setting Veterinarian-directed use only after a complete diagnosis and only if a defensible patient-specific rationale exists without delaying established medical or surgical care
vetman score
Not rateable
No numerical score assigned
Evidence confidence: Medium
Georgia: Yes, human · № რ-033806 · Verified on 22 Oct 2026
Off-label use
Not rateable
A numerical product score cannot responsibly be assigned. Exact Bestoxol has a verifiable human formulation and Georgian registration, but no exact-product feline dose, ocular PK, target-animal safety or clinical outcome study was found. Dietary taurine is essential in cats and deficiency causes retinal degeneration, but that evidence concerns nutrition/systemic status, not topical 4% drops; it cannot establish Bestoxol efficacy, retinal delivery or reversal of established damage.
Taurine biology is real, but it does not create a product-specific veterinary claim. Bestoxol should remain an identity-documented, no-dose, not-rateable human ophthalmic product until direct dog/cat efficacy and safety evidence supports a defined clinical scope.
Important safety and use flags
No exact-product dog/cat efficacy, ocular PK, target-animal safety or dose study was found. Do not convert the human label or mechanistic taurine literature into a veterinary product score. Feline taurine deficiency is a nutritional/systemic disorder. Diagnose diet and systemic status and correct dietary taurine; topical Bestoxol is not proven to deliver therapeutic retinal taurine or reverse established degeneration. The preliminary canine cataract study tested a multi-ingredient antioxidant formulation, not Bestoxol or taurine alone. Its unmasked, nonplacebo design and combined actives cannot establish this product’s efficacy or regimen. Do not copy the human two-drop, multi-month cataract/corneal-trauma or glaucoma schedule. No diagnosis-independent dog/cat frequency or course is published here. Do not delay established diagnosis or treatment of cataract, corneal injury, retinal disease, glaucoma, uveitis or infection. Progressive pain, redness, opacity, discharge, pressure change or vision loss requires prompt ophthalmic reassessment. The exact solution contains methyl parahydroxybenzoate. Stop and reassess for irritation, lid swelling, erythema, pruritus or another hypersensitivity reaction; target-animal repeated-dose tolerance is unknown. Avoid dropper-tip contact with the eye, lashes, skin or fingers, recap promptly and do not share a bottle between patients. Follow the exact pack’s storage and post-opening instructions. Safety in pregnant, lactating, breeding or juvenile dogs and cats is not established. Use only after an explicit veterinary benefit-risk decision, and do not infer safety from taurine being a normal nutrient. Current Georgian human registration does not imply veterinary authorisation or efficacy. The controlled EU/GB/US exact-brand negative findings describe market status only and are not used as proof that the product is ineffective. Assessment sources +
Close
Administration route
Into the eye
Registration
Georgia
Yes, human
In force until 17 Nov 2026
Human (Ministry of Health, RAMA)
№ რ-033806
Verified on: 22 Oct 2026
EU
No
UK
No
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified
No dog/cat dose or veterinary indication is established for this exact product. Do not copy the human multi-month cataract, corneal-trauma or glaucoma schedules. Feline dietary taurine deficiency requires nutritional/systemic management and is not an indication for these topical drops.
